Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Dollar General Corp. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Dollar General Corp. trades at $120.04 (market cap $27.00B). The key difference: Dollar General Corp. is far larger — about 31.3× Amphastar Pharmaceuticals Inc's market cap, and Dollar General Corp. pays a 1.93% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DG | |
|---|---|---|
Market Cap | $863.95M | $27.00B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $156.26 |
52-Week Low | $16.87 | $95.94 |
Enterprise Value | $1.26B | $41.45B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Dollar General (DG) trades at $126.59, down 0.69% on the day, with strong technical momentum indicated by bullish moving averages and oversold RSI conditions. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.00 exceeding expectations of $1.89, while maintaining solid profitability metrics including 18.91% ROE. Recent cash flow trends show improvement with 2025 net cash flow of $395 million, and the balance sheet reflects declining debt-to-asset ratios from 22.73% to 20.03% year-over-year.
The outlook remains positive with analyst consensus favoring Buy ratings (52%) and a $128.45 price target offering modest upside. Key opportunities include consumer trade-down benefits and margin improvement, while risks involve competition from Walmart and Amazon, market saturation concerns, and ongoing cost pressures. The stock presents a value proposition with attractive P/S (0.65) and P/E (17.91) multiples relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
